Performance of Clinical and Biochemical Parameters in Identifying Renal Histopathology and Predictors of One-Year Renal Outcome in Lupus Nephritis—A Single Centre Study from India
暂无分享,去创建一个
C. Kavadichanda | D. Bairwa | V. Negi | M. Thabah | C. Mariaselvam | S. Mehra | B. Srinivas | Sanket Shah | A. Gopal
[1] G. Cattoretti,et al. Dissecting the histological features of lupus nephritis highlights new common patterns of injury in class III/IV , 2022, Annals of the Rheumatic Diseases.
[2] J. Kothari,et al. Long-term outcome and predictors of long-term outcome in patients with lupus nephritis managed at a tertiary hospital in Mumbai , 2022, Lupus.
[3] E. Taylor,et al. Antihypertensive effects of immunosuppressive therapy in autoimmune disease , 2022, Journal of Human Hypertension.
[4] S. Quaglini,et al. Beyond ISN/RPS Lupus Nephritis Classification: Adding Chronicity Index to Clinical Variables Predicts Kidney Survival , 2021, Kidney360.
[5] L. Trupin,et al. High Disease Severity Among Asian Patients in a US Multiethnic Cohort of Individuals With Systemic Lupus Erythematosus , 2020, Arthritis care & research.
[6] S. Quaglini,et al. Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis , 2020, Annals of the Rheumatic Diseases.
[7] E. Frangou,et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis , 2020, Annals of the Rheumatic Diseases.
[8] Systemic Lupus Erythematosus Disease Activity Index , 2020, Definitions.
[9] T. Nishino,et al. Complete renal response at 12 months after induction therapy is associated with renal relapse-free rate in lupus nephritis: a single-center, retrospective cohort study , 2019, Lupus.
[10] B. Rovin,et al. Outcome of participants with nephrotic syndrome in combined clinical trials of lupus nephritis , 2019, Lupus Science & Medicine.
[11] Agnes B. Fogo,et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. , 2018, Kidney international.
[12] V. Negi,et al. Comparing the efficacy of low-dose vs high-dose cyclophosphamide regimen as induction therapy in the treatment of proliferative lupus nephritis: a single center study , 2018, Rheumatology International.
[13] C. Putterman,et al. Tubulointerstitial damage predicts end stage renal disease in lupus nephritis with preserved to moderately impaired renal function: A retrospective cohort study. , 2018, Seminars in arthritis and rheumatism.
[14] B. Rovin,et al. Update on Lupus Nephritis. , 2017, Clinical journal of the American Society of Nephrology : CJASN.
[15] Vladimir Tesar,et al. Understanding Histolopathologic Characteristics to Predict Renal Outcomes in Lupus Nephritis. , 2017, Clinical journal of the American Society of Nephrology : CJASN.
[16] Ron Wolterbeek,et al. Clinical and Histopathologic Characteristics Associated with Renal Outcomes in Lupus Nephritis. , 2017, Clinical journal of the American Society of Nephrology : CJASN.
[17] K. Gupta,et al. Effect of Thrombotic Microangiopathy on Clinical Outcomes in Indian Patients With Lupus Nephritis , 2017, Kidney international reports.
[18] T. J. Kim,et al. Risk factors to predict the development of chronic kidney disease in patients with lupus nephritis , 2017, Lupus.
[19] B. Rovin,et al. Current and Emerging Therapies for Lupus Nephritis. , 2016, Journal of the American Society of Nephrology : JASN.
[20] W. van Biesen,et al. Renal Biopsy in 2015 - From Epidemiology to Evidence-Based Indications , 2016, American Journal of Nephrology.
[21] M. Clark,et al. The Pathogenesis and Therapeutic Implications of Tubulointerstitial Inflammation in Human Lupus Nephritis. , 2015, Seminars in nephrology.
[22] J. Lane,et al. Practice patterns and approach to kidney biopsy in lupus: a collaboration of the Midwest pediatric nephrology consortium and the childhood arthritis and rheumatology research alliance , 2015, Pediatric Rheumatology.
[23] B. Rovin,et al. Predictors of Long‐Term Renal Outcome in Lupus Nephritis Trials: Lessons Learned from the Euro‐Lupus Nephritis Cohort , 2015, Arthritis & rheumatology.
[24] A. Ahmadi,et al. Clinicopathological correlations in lupus nephritis; a single center experience , 2014, Journal of nephropathology.
[25] D. Gladman,et al. Time to Recovery from Proteinuria in Patients with Lupus Nephritis Receiving Standard Treatment , 2014, The Journal of Rheumatology.
[26] J. Ahearn,et al. Biomarkers in systemic lupus erythematosus: challenges and prospects for the future , 2013, Therapeutic advances in musculoskeletal disease.
[27] H. Yamanaka,et al. Frequency of Class III and IV Nephritis in Systemic Lupus Erythematosus Without Clinical Renal Involvement: An Analysis of Predictive Measures , 2012, The Journal of Rheumatology.
[28] T. Cheng,et al. Age- and gender-related long-term renal outcome in patients with lupus nephritis , 2011, Lupus.
[29] T. Utset,et al. Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring , 2011, Arthritis care & research.
[30] M. Mok,et al. Do Asian patients have worse lupus? , 2010, Lupus.
[31] E. Bonfá,et al. Male gender results in more severe lupus nephritis , 2010, Rheumatology International.
[32] I. Bruce,et al. Numerical scoring for the BILAG-2004 index , 2010, Rheumatology.
[33] Su-xia Wang,et al. Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis. , 2009, Kidney international.
[34] D. Isenberg,et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. , 2009, Journal of the American Society of Nephrology : JASN.
[35] Lee Hebert,et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. , 2004, Kidney international.
[36] D. Gladman,et al. Systemic lupus erythematosus disease activity index 2000. , 2002, The Journal of rheumatology.
[37] Joni K. Evans,et al. Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. , 2001, Kidney international.
[38] L R Muenz,et al. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. , 1984, Kidney international.
[39] V. Jha,et al. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis. , 2016, Kidney international.
[40] J. Ioannidis,et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. , 2000, Kidney international.